Flare Therapeutics Inc. has patented peroxisome proliferator-activated receptor γ (PPARγ, PPARG) inverse agonists reported to be useful for the treatment of bladder cancer.
Researchers at Firefly Bio Inc. have prepared antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting HER2 covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonists through a linker. They are reported to be useful for the treatment of cancer, autoimmune disease, inflammation and infections.
Several Insilico Medicine Inc. patents describe diacylglycerol kinase α (DGK-α, DGKA) inhibitors reported to be useful for the treatment of cancer and viral infection.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified 3-alkynyl carboxamides acting as legumain (asparaginyl endopeptidase; LGMN) inhibitors.
Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have jointly described new phosphatidylinositol 3-kinase (PI3K) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Immuther Pharmtech (Shanghai) Co. Ltd. has patented lysophosphatidic acid LPA5 receptor (GPR92) antagonists reported to be useful for the treatment of neuropathic pain, cancer, neurological disorders, atherosclerosis, inflammatory and autoimmune diseases, fibrosis and obesity, among others.
China Welfare Institute International Peace Maternity and Child Health Hospital and East China University of Science & Technology have jointly developed aza-phenothiazine derivatives reported to be useful for the treatment of endometrial cancer.
Leo Pharma A/S researchers have synthesized new interleukin-17 (IL-17) modulators reported to be useful for the treatment of psoriasis, psoriatic arthritis, spondyloarthritis, radiographic ankylosing spondylitis (ankylosing spondylitis) and autoimmune diseases.
RSS